The UT MD Anderson Cancer Center Community Clinical Oncology Program Research Bas

UT MD 安德森癌症中心社区临床肿瘤学项目研究基地

• 批准号: 8308101
• 负责人: MICHAEL Jordan FISCH
• 金额: $ 138.96万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-09-30 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8308101
• 关键词: Acupuncture procedure; Acute; Affect; Area; Basic Science; Behavior; Belief; Biological Factors; Cancer Center; Cancer Control; Cancer Control Research; Cancer Patient; Caring; Chronic; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Design; Collection; Communication; Communities; Community Clinical Oncology Program; Conduct Clinical Trials; Controlled Study; Counseling; Data; Division of Cancer Prevention; Exercise; Faculty; Family; Goals; Health; Instruction; Internal Medicine; Intervention; Knowledge; Late Effects; Leadership; Malignant Neoplasms; Medicine; Mentorship; Mind-Body Intervention; NCI Center for Cancer Research; Oncologist; Outcome; Patient Care; Patient Outcomes Assessments; Patients; Personal Satisfaction; Population; Population Sciences; Prevention; Process; Prospective Studies; Quality of life; Research; Research Personnel; Resources; Risk; Science; Scientist; Site; Social Marketing; Structure; Toxic effect; University of Texas M D Anderson Cancer Center; Women Physicians; Work; active method; base; cancer recurrence; cancer therapy; community setting; design; disorder prevention; improved; innovation; novel strategies; pre-clinical; programs; psychologic; rapid growth; research study; response; social; survivorship

DESCRIPTION (provided by applicant): The MD Anderson Cancer Center CCOP Research Base (RB) is a venue for transdisciplinary cancer control research within MDACC, and connecting this research to community oncologists and other academic centers, in order to improve patient care. Hypothesis: our cancer center RB, using its full breadth and scope of clinicians, basic and population science researchers, community partners, and robust expertise in all aspects of clinical investigation, while leveraging the resources available at MDACC, can create and disseminate critical new knowledge in cancer control through the process of team science and clinical research innovation. Specific aims: Aim 1. To conduct interventional clinical trials and other prospective studies in the realm of cancer control to enhance the health and well-being of patients affected by cancer or at risk for cancer recurrence. (1a) To develop and conduct clinical trials and other prospective studies in integrative health in order to optimize health, quality of life, and clinical outcomes of patients and families across the cancer continuum; (1b) To develop and conduct interventional trials and prospective studies directed at understanding and reducing the burden of cancer treatment toxicity; (1c) To incorporate novel approaches to the design, conduct, and analysis of clinical trials. Aim 2. To promote cancer control science among our community oncology sites, academic cancer center faculty and fellows, and the lay public. (2a) To enhance interactions between preclinical and clinical investigators to better inform the design of clinical trials and enhance the collection and interpretation of pilot data and correlative science; (2b) To develop cancer control studies relevant to all stakeholders and involving the collection of patient-reported outcome data and data related to observed patient behaviors; (2c) To use multiple modes of communication to disseminate the healthy goals and step-by-step processes involved in cancer control research; (2d) To use mentorship and institutional leadership to promote the inclusion of young investigators and women physicians and scientists in the CCOP research base; (2e) To develop and share best practices for the inclusion of underrepresented populations in our clinical research studies and on our research teams. RELEVANCE (See instructions): The MD Anderson Cancer Center CCOP Research Base delivers innovative studies directly to patients in the community setting, in order to improve patient care and facilitate the discovery and dissemination of new information that impacts the field of cancer medicine.

描述（由申请人提供）：MD安德森癌症中心CCOP研究基础（RB）是MDACC内跨学科癌症控制研究的场所，并将这项研究与社区肿瘤学家和其他学术中心联系起来，以改善患者护理。假设：我们的癌症中心RB使用其在临床调查的各个方面的临床医生，基础和人口科学研究人员，社区伙伴以及强大的专业知识的全部广度和范围，同时利用MDACC可用的资源，可以通过团队科学和临床研究创新的过程来创建和传播对癌症控制的关键新知识。具体目的：目标1。在癌症控制领域进行介入的临床试验和其他前瞻性研究，以增强受癌症影响或有癌症复发风险的患者的健康和福祉。 （1a）为了优化整个癌症连续体的患者和家庭的健康，生活质量和临床结果，开发和进行综合健康方面的临床试验和其他前瞻性研究； （1B）开发和进行介入的试验和前瞻性研究，旨在理解和减轻癌症治疗毒性的负担； （1C）结合了临床试验设计，进行和分析的新方法。目的2。促进我们社区肿瘤学场所，学术癌症中心和研究员以及外行公众之间的癌症控制科学。 （2a）增强临床前研究者和临床研究者之间的相互作用，以更好地为临床试验的设计提供信息，并增强对试验数据和相关科学的收集和解释； （2B）开发与所有利益相关者相关的癌症控制研究，并涉及收集患者报告的结果数据和与观察到的患者行为有关的数据； （2C）使用多种沟通方式来传播癌症控制研究涉及的健康目标和逐步的过程； （2d）使用指导和机构领导才能促进CCOP研究基础中的年轻研究人员，女医生和科学家的包含； （2E）开发和共享最佳实践，以在我们的临床研究和研究团队中包含代表性不足的人群。 相关性（请参阅说明）：MD Anderson癌症中心CCOP研究基础直接向社区中的患者提供创新研究，以改善患者护理并促进影响和传播影响癌症医学领域的新信息。